-+ 0.00%
-+ 0.00%
-+ 0.00%

NeOnc Technologies hosts call on Phase 2a topline data for intranasal NEO100 in recurrent IDH1-mutant glioma

PUBT·08/10/2026 12:31:44
Listen to the news
NeOnc Technologies hosts call on Phase 2a topline data for intranasal NEO100 in recurrent IDH1-mutant glioma
  • NeOnc Technologies scheduled an Aug. 12, 2026 investor call to present topline Phase 2a results for intranasal NEO100.
  • Results have not yet been presented; management plans to disclose efficacy and safety observations from the NEO100-01 study.
  • The trial evaluates NEO100 in recurrent or progressive Grade III-IV IDH1-mutant high-grade glioma, a setting with limited treatment options.
  • Planned regulatory next steps will be discussed, signaling potential progression toward later-stage development if findings support it.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100830PRIMZONEFULLFEED9806521) on August 10, 2026, and is solely responsible for the information contained therein.